Biomimetic intelligent lipoprotein nanocarrier for sustained and well-tolerated nerve growth factor delivery in neurotrophic keratopathy treatment
Journal of Controlled Release · 2026-11 · 399 · 115358
DOI: 10.1016/j.jconrel.2026.115358 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-11. Verfasst von Shiding Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, …. Hauptthemen laut MEDLINE: Nerve Growth Factor, Corneal Diseases, Nanoparticles, Drug Carriers. Die Arbeit nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Neurotrophic keratopathy (NK) is a degenerative disorder arising from trigeminal/corneal nerve impairment and may progress to persistent epithelial defects, ulceration, perforation, and vision loss. Although recombinant human nerve growth factor (rhNGF) has been approved for NK treatment, its clinical use is limited by low ocular bioavailability, irritation, and frequent dosing (six times daily). Here, we developed a biomimetic intelligent enzyme-responsive lipoprotein (NGFc-L@P) for sustained and well-tolerated delivery of NGF. NGFc-L@P features (i) an outer shell of reconstituted high-density lipoprotein (rHDL) functionalized with matrix metalloproteinase-9 (MMP-9)-activatable cell-penetrating peptides, enabling lesion-responsive activation and enhanced corneal penetration; and (ii) an inner core that mimics the extracellular matrix and encapsulates NGF, preserving its bioactivity while providing sustained release. Compared with conventional NGF formulations, NGFc-L@P prolonged corneal NGF residence to >8 h, enabled sustained release, mitigated ocular irritation and enabled targeted penetration. In alkali burn-induced NK mouse models, NGFc-L@P markedly accelerated corneal epithelial healing, promoted nerve restoration and suppressed inflammation with three daily instillations. Besides, diabetes NK mice were established to further validate superior therapeutic efficacy and universality of NGFc-L@P. Collectively, this biomimetic intelligent lipoprotein nanocarrier provides a promising strategy for NK therapy in a multi-dimensional manner and holds strong potential for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Orbital Diseases and Ocula…
- Department of Pharmacology and Chemical Biology, Collaborative Innovation Center for Clinical and Translational Science by Chinese Ministry of Education & Shanghai, Shanghai Jiao Tong University School of Medicine, Shan…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, S., Huang, J., Zhang, S., Wu, N., Sun, H., Chen, L., Gao, X., & Fu, Y. (2026). Biomimetic intelligent lipoprotein nanocarrier for sustained and well-tolerated nerve growth factor delivery in neurotrophic keratopathy treatment. Journal of Controlled Release, 399, 115358. https://doi.org/10.1016/j.jconrel.2026.115358
Vancouver
Li S, Huang J, Zhang S, Wu N, Sun H, Chen L, et al. Biomimetic intelligent lipoprotein nanocarrier for sustained and well-tolerated nerve growth factor delivery in neurotrophic keratopathy treatment. Journal of Controlled Release. 2026;399:115358. doi:10.1016/j.jconrel.2026.115358
BibTeX
@article{Li2026,
author = {Li, Shiding and Huang, Jialin and Zhang, Siyi and Wu, Nianxuan and Sun, Hao and Chen, Liangbo and Gao, Xiaoling and Fu, Yao},
title = {Biomimetic intelligent lipoprotein nanocarrier for sustained and well-tolerated nerve growth factor delivery in neurotrophic keratopathy treatment},
journal = {Journal of Controlled Release},
year = {2026},
volume = {399},
pages = {115358},
doi = {10.1016/j.jconrel.2026.115358}
}
EUVIMED